On June 25, 2024, a wallet linked to Ansem withdrew 504.5 SOL from an exchange in two transactions, valued at about $69,000. That same day, 377.43 SOL, worth approximately $52,300, was transferred to Ansem's main wallet. Earlier, on May 31, 2024, the exchange's hot wallet sent 99.06 SOL (about $16,400) to the linked wallet shortly after the issuance of JENNER and MOTHER tokens. These movements highlight significant SOL transfers connected to Ansem's wallets, which may indicate strategic asset management or preparation for further transactions.
The recent Solana (SOL) wallet activity linked to Ansem provides context for readers interested in cryptocurrency movements. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 09, 2026 02:21 WIB: out of 50 major cryptocurrencies, 8 rose and 41 fell today. Notable movers include KSM (Kusama) at Rp56.695 with a 1-day change of -3.97%, SNX (Synthetix) at Rp2.915 with a 1-day change of -3.64% and a Pluang order activity of 34% Sell / 66% Buy, and GRT (The Graph) at Rp337 with a 1-day change of -3.32% and a Pluang order activity of 10% Sell / 90% Buy.
NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
